{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005294","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2026-08-06T12:00:37+00:00","discovered_at":"2026-08-06T12:05:14.508599+00:00","generated_at":"2026-08-06T12:06:11.553741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q2 net loss narrows to $1.5M; cash runway through Q4 2026","bullets":["Net loss of $1.5M ($0.14 per share) vs $15.9M ($1.53) in Q2 2025; improvement driven by $3.0M warrant fair value gain.","Cash, equivalents and investments $30.4M at June 30, 2026, down from $77.8M at Dec 31, 2025; expects funding through Q4 2026.","Received $25M upfront from Amoytop for Greater China license of pevifoscorvir sodium; $3M milestone from ALG-170675 IND approval expected Q3 2026.","Phase 2 B-SUPREME study of pevifoscorvir sodium fully enrolled (245 participants); topline data expected late Q3 2027.","R&D expenses rose to $24.1M from $14.0M due to Phase 2 trial costs; G&A flat at $5.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005294","json":"https://secwatch.observer/filing/0001171843-26-005294.json","markdown":"https://secwatch.observer/filing/0001171843-26-005294.md","text":"https://secwatch.observer/filing/0001171843-26-005294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/0001171843-26-005294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/f8k_080526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:06:11.553741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}